No influence of KIF1B on neurodegenerative markers in multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In search of genetic causes of multiple sclerosis (MS), a number of genes have consistently shown association with MS susceptibility in the past couple of years.1 All of these identified genes are directly or indirectly involved with the inflammatory process. However, it has become increasingly clear that MS consists of both an inflammatory and a progressive neurodegenerative process,2 which is illustrated by the fact that new and potent anti-inflammatory drugs have been unable to halt neurodegeneration. The relation between episodes of inflammation and the neurodegenerative component characterized by irreversible axonal loss are far from clear at this point. Some authors have argued that neurodegeneration is independent of inflammation, while others argue that the 2 components are closely associated and are actually interdependent.2,3 The neurodegenerative component is clinically highly relevant since it is held predominantly responsible for disability accumulation, although several questions regarding this issue remain.2 Until recently, no genetic marker for neurodegeneration in MS was identified. However, in 2008, it was reported for the first time that a “neurodegenerative gene,” i.e., the KIF1B rs10492972 [C] variant, was associated with MS susceptibility.4 KIF1B is involved in axonal transport of mitochondria and synaptic vesicle precursors. Dysregulation of axonal transport plays a role in several neurodegenerative diseases.4 The authors suggested that KIF1B could be the first gene involved in MS susceptibility with a possible neurodegenerative effect.4 Unfortunately, this finding could later not be confirmed in other …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David Beversdorf and Dr. Ryan Townley
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosisErnst-Wilhelm Radue, Frederik Barkhof, Ludwig Kappos et al.Neurology, January 28, 2015 -
Articles
APOE epsilon variation in multiple sclerosis susceptibility and disease severitySome answersR. M. Burwick, P. P. Ramsay, J. L. Haines et al.Neurology, May 08, 2006 -
Article
Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studiesMichaela F. George, Farren B.S. Briggs, Xiaorong Shao et al.Neurology: Genetics, August 04, 2016 -
Articles
Cigarette smoking and progression in multiple sclerosisMarcus Koch, Annemarie van Harten, Maarten Uyttenboogaart et al.Neurology, October 08, 2007


